Globe Newswire09.21.21
CareDx Inc., a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that Hannah Valantine, M.D., has joined the company’s Board of Directors.
Valantine is a professor of Medicine at Stanford and the former National Institutes of Health (NIH) chief scientific officer for Scientific Workforce Diversity. Prior to joining the NIH, she was professor of Cardiovascular Medicine and the senior associate dean for Diversity and Leadership at Stanford. Valantine has partnered with CareDx throughout the years, including as a principal investigator on the seminal AlloMap Heart publications and as an innovator behind the original patents for AlloSure alongside Dr. Stephen Quake at Stanford.
“I have dedicated my professional life to biomarker development in transplant medicine. Looking back, it is incredible to see the impact we have had on patient care, particularly with inclusive research and development practices. I am glad to join the CareDx board where I can continue working closely with Reg and the team, who are pioneers in an incredibly important field. We are supporting the transplant community with more and more tools to further our evidence-driven approaches in a high-impact patient setting,” said Valantine.
“We welcome Hannah to the CareDx Board of Directors. Hannah will not only greatly contribute to our Scientific Advisory Committee, she will also provide the transplant clinician perspective from her many years of clinical experience at Stanford. In her role at the NIH, she has been able to drive an innovation agenda and influence policy on the national stage,” said Peter Maag, executive board chairman at CareDx Inc.
CareDx Inc., headquartered in South San Francisco, is a precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions along the pre- and post-transplant patient journey and provides genomics-based information for transplant patients.
Valantine is a professor of Medicine at Stanford and the former National Institutes of Health (NIH) chief scientific officer for Scientific Workforce Diversity. Prior to joining the NIH, she was professor of Cardiovascular Medicine and the senior associate dean for Diversity and Leadership at Stanford. Valantine has partnered with CareDx throughout the years, including as a principal investigator on the seminal AlloMap Heart publications and as an innovator behind the original patents for AlloSure alongside Dr. Stephen Quake at Stanford.
“I have dedicated my professional life to biomarker development in transplant medicine. Looking back, it is incredible to see the impact we have had on patient care, particularly with inclusive research and development practices. I am glad to join the CareDx board where I can continue working closely with Reg and the team, who are pioneers in an incredibly important field. We are supporting the transplant community with more and more tools to further our evidence-driven approaches in a high-impact patient setting,” said Valantine.
“We welcome Hannah to the CareDx Board of Directors. Hannah will not only greatly contribute to our Scientific Advisory Committee, she will also provide the transplant clinician perspective from her many years of clinical experience at Stanford. In her role at the NIH, she has been able to drive an innovation agenda and influence policy on the national stage,” said Peter Maag, executive board chairman at CareDx Inc.
CareDx Inc., headquartered in South San Francisco, is a precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions along the pre- and post-transplant patient journey and provides genomics-based information for transplant patients.
